Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sinopharm Group Co ( (HK:1099) ) has shared an announcement.
Sinopharm Group has scheduled a board meeting for 20 March 2026 to review and approve the consolidated annual results for the year ended 31 December 2025. The board will also consider the declaration of any dividends, a decision that could influence shareholder returns and signal management’s view of the company’s financial health.
The announcement also reiterates the current composition of Sinopharm’s board, listing its executive, non-executive and independent non-executive directors. This disclosure underscores the company’s governance structure and may be of interest to investors tracking board oversight and leadership stability at the pharmaceutical group.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical distributor and healthcare services provider, listed in Hong Kong and operating through a network of subsidiaries across the People’s Republic of China. The company focuses on the distribution of medicines, medical devices and related healthcare products, serving hospitals, pharmacies and other medical institutions nationwide.
Average Trading Volume: 5,106,654
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$64.41B
See more insights into 1099 stock on TipRanks’ Stock Analysis page.